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Abstract
Mutations in the TP53 gene are the most common alterations in human tumours. TP53 mutational patterns have sometimes
been linked to carcinogen exposure. In hepatocellular carcinoma, a specific G.T transversion on codon 249 is classically
described as a fingerprint of aflatoxin B1 exposure. Likewise G.T transversions in codons 157 and 158 have been related to
tobacco exposure in human lung cancers. However, controversies remain about the interpretation of TP53 mutational
pattern in tumours as the fingerprint of genotoxin exposure. By using a functional assay, the Functional Analysis of
Separated Alleles in Yeast (FASAY), the present study depicts the mutational pattern of TP53 in normal human fibroblasts
after in vitro exposure to well-known carcinogens: benzo[a]pyrene, aflatoxin B1 and acetaldehyde. These in vitro patterns of
mutations were then compared to those found in human tumours by using the IARC database of TP53 mutations. The
results show that the TP53 mutational patterns found in human tumours can be only partly ascribed to genotoxin exposure.
A complex interplay between the functional impact of the mutations on p53 phenotype and the cancer natural history may
affect these patterns. However, our results strongly support that genotoxins exposure plays a major role in the aetiology of
the considered cancers.
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Introduction
Somatic mutations are a key event in carcinogenesis and it is
now well recognised that carcinogenesis involves heritable genetic
factors as well as epigenetic changes. The turning point during the
cancer initiation is the acquisition of targeted somatic mutations
which confers to cells a selective advantage for clonal proliferation.
Among the many different genes involved in this process, TP53
remains the most frequently mutated in human cancers,
accounting for over 70% of all the mutations described so far in
human cancers [1]. The International Agency for Research on
Cancer (IARC) TP53 mutation database contains 27,580 somatic
TP53 mutations (http://www-p53.iarc.fr/, R15 release) [2]. In
contrast to other tumour suppressor genes, the vast majority of
TP53 mutations are missense rather than non sense or frameshift
mutations, leading to various patterns in different cancers.
Interestingly, these patterns have been sometimes linked to
exposure of aetiological factors such as UV light in skin carcinoma
[3], tobacco in lung cancers [4], aflatoxin B1 in hepatocarcinoma
[5] or aristolochic acid in renal carcinoma [6,7]. However,
interpretation of TP53 mutational pattern in tumours as a
fingerprint of genotoxin exposure remains controversial [8].
Indeed, mutations resulting from exposure to genotoxins and
other cellular events arising during carcinogenesis affect the final
mutational profile found in human tumours, e.g. clonal selection of
particular mutants, the genetic instability in cancerous cells or
epigenetic influences (e.g. methylation status) [9–11].
As many TP53 mutations found in tumours strongly affect p53
functional properties [12], a functional assay, the Functional
Analysis of Separated Alleles in Yeast (FASAY) appears as an
useful technique to distinguish between silent mutations in TP53
and those that render the protein inactive [13,14]. DNA from a
variety of sources can be screened by FASAY for the presence of a
TP53 allele encoding a dysfunctional protein. We previously
described mutational patterns in normal human fibroblasts after in
vitro exposure to acetaldehyde and aflatoxin B1 (AFB1) by using
FASAY [15,16]. Here, we have completed these data with those
obtained with a well-known genotoxin: benzo[a]pyrene (B[a]P).
Exposure to B[a]P and AFB1 results in the formation of bulky
adducts predominantly targeting guanine. We will discuss how
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different tumours.
Further, the experimentally-generated TP53 mutational pat-
terns were compared with those in related tumours recorded in the
IARC database [2]. The mutational pattern of B[a]P was
compared to those of lung cancers and discussed thoroughly in
the present paper. This enabled us to discuss the causality of
genotoxins exposure to the human cancer mutational patterns.
Materials and Methods
Cell line and cell culture
Human diploid fibroblasts AG1521 (Coriell Institute, Camden,
NJ) were chosen for this study. Absence of pre-existing mutations
in TP53 locus in these cells was confirmed by sequencing genomic
DNA with a Beckman Automated Sequencer (CEQ 8000). Cells
were cultured at 37uC in a humidified atmosphere of 5% CO2 and
95% air, in Eagle’s Minimal Essential Medium (MEM) supple-
mented with 10% inactivated foetal bovine serum (FBS). Before
exposure to the genotoxin, the medium was completed with 200 ml
(4%) of S9 liver microsomal fraction of phenobarbital- and
naphtoflavone-treated rats (Biopredic, Rennes, France), NADPH
(4 mM) and G6P (5 mM). The required amount of B[a]P (Sigma,
CAS number: 50-32-8, up to 200 mM) was diluted in the above
medium and used to treat cells for 2 h at 37uC. Post-exposure, the
culture plates were washed three times with PBS and incubated in
fresh medium. As the doubling time of these cells is around 3 days,
incubation period of one week was chosen to allow two cell cycles
and ensure fixation of mutations.
Cytotoxicity study
AG1521 fibroblasts were exposed to B[a]P at concentrations
from 1 to 200 mM in the presence of S9, for 2 h at 37uC in 96-well
micro-plates. The plates were washed three times with PBS and
incubated for 3 days at 37uC. Cytotoxicity was evaluated with an
XTT assay (Sigma) according to the Scudiero protocol [17].
Post-labelling
Post-labelling method was adapted from Reddy and Randerath
[18]. Genomic DNA was extracted using the classical phenol/
chloroform method after treatment by RNAse A and T1 followed
by proteinase K (Sigma-Aldrich) and post-labelling assay was then
performed as previously described [19]. From the autoradiograms
thus obtained, spots corresponding to the adducts were excised for
measuring radioactivity. Results are expressed as Relative Adduct
Levels (RAL) calculated as followed: RAL=(cpmadducts/
cpmBPDE)6110.7610
28, where cpmadducts and cpmBPDE corre-
spond to counts per minute from the excised spots and from the
positive control issued from calf thymus exposed to B[a]P-7,8-
Dihydrodiol-9,10-Epoxide (BPDE), and carrying 110.7 adducts for
10
28 normal nucleotides as measured elsewhere [20]. Positive
control was kindly supplied by F. Beland, Jefferson, USA.
FASAY
RNA extraction and Reverse Transcription (RT)-PCR were
performed as previously described [15]. To amplify the cDNA
primers containing a phosphorothioate linkage at the 39 end
were designed : P3 [59-ATT-TGA-TGC-TGT-CCC-CGG-ACG-
ATA-TTG-AA(s)C-39] and P4 [59-ACC-CTT-TTT-GGA-CTT-
CAG-GTG-GCT-GGA-GT(s)G-39]. FASAY was done according
to Flaman et al. [14], with some modifications as previously
described [15]. Plasmid pSS16 and yeast strain YIG397 were
generously donated by J.M. Flaman (INSERM U614, Rouen,
France) and J. Cachot (LEMA EA3222, Le Havre, France),
respectively.
TP53-expressing plasmids were rescued from isolated red
colonies which were returned to culture and lysed with Zymolyase
(MP-Biomedicals). Purelink Quick Plasmid Miniprep KitH (In-
vitrogen) was used to rescue the plasmids. Before sequencing,
TP53 cDNA was re-amplified with primers P5 [59-TCT-GTC-
ACT-TGC-ACG-TAC-TCC-39] and P6 [59-AGA-GGA-GCT-
GGT-GTT-GTT-GG-39], designed to cover exon 4–9 according
to sequence described in GenBank (NM_000546). Two sets of
primers were chosen to sequence the recombination sites on either
side of the TP53 cDNA: at 59 region primers PA [59-CAG-TCA-
GAT-CCT-AGC-GTC-GAG-39] and PB [59-CTC-CGT-CAT-
GTG-CTG-TGA-CT-39]; at 39 region primers PC [59-AAG-
GAA-ATT-TGC-GTG-TGG-AG-39] and PD [59-CAG-GCC-
CTT-CTG-TCT-TGAAC-39].
Sequence tools analysis
The Thierry Soussi database (http://p53.free.fr/) was used a
reference for the TP53 wild type sequence and the IARC database
R14 release (http://www-p53.iarc.fr/) was used for comparing
different TP53 mutational patterns [2]. BLAST tool from NCBI
(http://www.ncbi.nlm.nih.gov/) was used for analysis of sequence
similarities.
Statistical analysis
Statistical analysis was done using the SAS Software release 9.2.
A chi square test with one degree of freedom was applied to
evaluate the correspondence between the observed and theoretical
frequencies of mutations out of the base substitutions in exons 4 to
9. Comparisons between the substitutions patterns pertaining to
the genotoxins were done using a Fisher’s exact test. All tests were
two sided with a significance level of 0.05.
Results
Cytotoxicity studies on AG1521 fibroblasts
Cell growth after 2 hours exposure of AG1521 human
fibroblasts to B[a]P at various concentrations showed a moderate
cytotoxicity of B[a]P in these conditions, the IC50 was estimated to
be above 200 mM (Figure 1). We then chose exposure concentra-
tions ranging from 1 mM corresponding to the higher concentra-
tion without any growth inhibition to 50 mM corresponding to a
25% growth inhibition. Thus, cellular damage was minimized and
resumption of culture was easier after exposure. The range of
concentrations of acetaldehyde and AFB1 used were previously
described and discussed [15,16]. Acetaldehyde was used at 0.1–
7.5 mM and AFB1 at 16–800 nM.
Post labelling of B[a]P induced DNA adducts
Figure 2A shows the pattern of DNA bulky adducts after
2 hours exposure to B[a]P 1, 10 and 50 mM in the presence of
exogenous metabolization fraction (S9mix). Positive control was
obtained from naked calf thymus DNA exposed to 35 nM BPDE,
the active metabolite (Figure 2B). A major spot migrating similarly
on the thin layer chromatography plates was visible in the four
samples. After B[a]P exposure, a second but very faint spot was
also observed for the 2 highest concentrations. The RAL in DNA
from B[a]P-exposed cells after exogenous metabolization were
significantly above the limit of quantification of 1.75610
28. This
value was determined after an internal process of validation
(unpublished data). This demonstrates the efficiency of the
metabolizing procedure. However, a plateau effect is reached at
10 mM.
Genotoxins Mutational Pattern in TP53
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Table 1 shows the overall results for the B[a]P. Each
concentration was tested in triplicate. As reproducibility among
triplicates was very high, the total number of colonies for each
concentration is shown.
Among the red colonies arising from untreated control cells,
only a few bear mutations in the central part of TP53, i.e. exons 4
to 9. The other red colonies were considered as artefacts as they
carried undigested pSS16 plasmid or mutations located in the
recombination sites. Among the 3 red colonies from control cells
bearing a mutation in the central part of TP53, 2 showed an AGT
insertion in exon 7/8 which is likely a splicing defect rather than a
true mutational event, as described earlier [15]. It is noteworthy
that the rate of this splicing defect was comparable among the
experiments on the three genotoxins discussed here. Only one true
mutation was found in the control cells, allowing the calculation of
a spontaneous mutation rate of 0.05%. This rate was around 9 to
18 times lower than the mutation rates calculated in exposed cells.
This single spontaneous mutation, was a G.A transition within a
CpG sequence in codon 267 (CGG.TGG). This kind of mutation
Figure 1. Cytotoxicity of B[a]P. Cytotoxicity of B[a]P to human fibroblastsAG1521 after 2 h exposure and 3 days recovery (4 wells per
concentration, means and standard deviations).
doi:10.1371/journal.pone.0030921.g001
Figure 2. Post-labelling DNA adduct patterns. (A) AG1521 cells after 2 hours exposure to B[a]P. (B) Calf thymus DNA after exposure to 35 nM
B(a)P-7,8-Dihydrodiol-9,10-Epoxide (BPDE control). RAL values are the mean of two independent assays.
doi:10.1371/journal.pone.0030921.g002
Genotoxins Mutational Pattern in TP53
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osine, although we cannot exclude the possibility of an error
introduced by the DNA polymerase during the RT-PCR step.
The mutation rates in exposed cells were comprised between
0.45 to 0.92%. As observed with post-labelling data, a plateau is
reached at 10 mM.
Identification of TP53 mutations in B[a]P exposed
AG1521 human fibroblasts
Table 2 shows the 37 true mutations found in B[a]P-exposed
cells. Five mutations were one- or more-base insertions/deletions,
leading to a frameshift. The remaining mutations were single
nucleotide substitutions including 1 nonsense and 25 missense
mutations. The mutational pattern is depicted in Figure 3C: G.T
transversions were the most prevalent (8/37, 21.6%). They are
followed by G.A, G.A at CpG and A.G transitions (7/37,
18.9% for each one of them), deletions (4/37, 10.8%), G.C
transversions (2/37, 5.4%), A.T transversions (1/37, 2.7%) and
one base insertion (1/37, 2.7%). This mutational pattern is then
discussed in comparison with that previously obtained after
AG1521 fibroblasts exposure to acetaldehyde (Figure 3A) and
aflatoxin B1 (AFB1, Figure 3B) [15,16].
Localization of mutations among TP53 exons 4 to 9
Figure 4 shows the localization of mutations from B[a]P (this
study), AFB1 and acetaldehyde [15,16]. B[a]P pattern shows two
hot-spots, codons 248 and 127, whereas AFB1 hot-spots are
codons 179 and 220 and acetaldehyde ones codons 248, 245 and
283.
In order to assess if the pattern of B[a]P mutations could be a
matter of chance, we analysed the data as described by Shen et al.
[21]. For this analysis of hot-spots, only base substitutions
occurring in exons 5 to 9 were taken into account. Hot-spots
were defined as the 24 mutations that account for 50% of the
mutations reported in lung cancer in the R14 IARC database. In
order of decreasing frequency, these are codons: 273, 248, 249,
245, 158, 157, 175, 179, 282, 220, 242, 163, 176, 154, 280, 266,
298, 237, 193, 281, 159, 135, 234 and 244. If these 24 hot-spots
were assumed to be randomly mutated, then they would be
predicted to be hit 24/205 (total number of codons in exons 5 to
9), i.e. at a frequency of 11.7%. Out of the 30 base substitutions in
exons 5 to 9 in our study, 11 (36.7%) correspond to one of the
above hotspots identified for lung cancers, a rate significantly
higher than that predicted for random events (11.7%; p=2.10
25).
The same analysis was performed using either only hot-spots
found in lung cancer from smokers, or another definition of hot-
spots, i.e. mutation frequency superior to 2% of all mutations as
proposed by Olivier et al. [22]. These analyses were highly
significant whatever the parameters used (data not shown).
These observations, together with the comparison of mutation
sites with the lung cancer hot-spots as shown above, strongly argue
against a random distribution of mutations in our assay.
Discussion
We will address two important issues: first, are experimentally
generated mutation profiles representative of those occurring
naturally for a given genotoxin? Secondly, based on a compilation
of experimental and epidemiological data on mutations associated
with human tumours, can chemically-induced mutations of TP53
at specific sites (codons) be identified as a key event in
carcinogenesis?
Relationship between B[a]P mutagenicity and TP53
mutations
Many genotoxic metabolites are produced from B[a]P. The
main way, which involves CYP1A, CYP1B, CYP3A and epoxide
hydrolases, leads to the ultimate genotoxic metabolite (6)-anti-
BPDE which binds to DNA and forms predominantly DNA
adducts at the N2 position of guanine and to a lesser extent at the
N6 position of adenine [23–25]. Another pathway involves
dihydrodiol dehydrogenases AKR1A1 and 1C1-4 which oxidize
B[a]P dihydrodiols to catechols [26]. Catechols can then undergo
mono-electronic oxidizations leading to o-quinones which form
Table 1. Summary of yeast transformations for B[a]P experiments.
Benzo[a]pyrene (mM)
Control cells 1 10 50
Yeast transformation
Total number of colonies A 4084 4890 5423 5240
Total number of red colonies B 97 148 220 181
Recovering of red colonies and PCR step
Analysed red colonies C 48 40 84 66
Red colonies bearing TP53 (PCR positive) D 37 39 77 60
Red colonies bearing non digested pSS16 (C–D) E 11 1 7 6
Sequencing step
Colonies mutated on exons 4 to 9 F 3 8 22 15
AGT insertion in exon 7/8 (splicing defect) G 2 2 3 3
‘‘True’’ mutations (F–G) H 1 6 19 12
Rate of mutation
Total number of ‘‘true’’ mutations (HxB/C) 2.0
a 22.2
a 49.8
a 32.9
a
Rate of mutation (%) 1006(HxB/C)/A 0.05 0.45 0.92 0.63
Data pooled from triplicates are shown.
aEstimated values.
doi:10.1371/journal.pone.0030921.t001
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2-dG and the B[a]P-
7,8-dione-N
6-dA [27,28]. In this study, during the exposure of
AG1521 fibroblasts to B[a]P, metabolizing enzymes were supplied
exogenously, according to the standard practices in genotoxicity
testing. The post-labelling analysis revealed a major spot that co-
migrated with that seen in control DNA exposed to BPDE. This
strongly suggests that B[a]P exposure results predominantly in
BPDE-DNA adducts.
In agreement with the data in literature, we found that the
majority of base substitutions induced by B[a]P were located on
G:C base pairs of which only 6 within CpG regions. Guanines in
methylated CpG sequences are typical targets for DNA adducts
[10,23]. It is likely that DNA methylation is poor in a cellular
model such as the one employed here, but Shen et al., using the
same reporter yeast strain transformed by chemically modified
plasmids, observed that DNA methylation did not affect the
generation of BPDE adducts [21].
Using UvrABC endonuclease in combination with ligation-
mediated PCR (LMPCR), the distribution of BPDE adducts on
exons 5, 7 and 8 of TP53 in HeLa cells have been mapped [29,30].
Strong adduct formation occurred at the guanines in codons 154,
156, 157, 158, 159, 245, 248 and 273, most of which are described
as hot-spots in lung cancers (157, 158, 245, 248, and 273; IARC
database, version R14). Indeed, the codon 248 was most
frequently targeted by B[a]P in our assay. Secondly, using
methylated and BPDE-exposed DNA fragments containing exon
5o fTP53, adducts were found at three other codons: 152, 175,
181, all of which were uncovered in the present study as well [10].
B[a]P induced mutational patterns have been extensively
studied in many genes in various biological systems. Assays
conducted in rodent cells in vitro or in vivo on reporter genes such as
HPRT or LacI have consistently reported the predominance of
G.T transversions and, to a lesser extent, of G.A transitions and
deletions [31–34]. The rate of G.T transversions seems to be
Table 2. Summary of TP53 mutations found in B[a]P exposed-cells (Cc: concentration).
Number Cc (mM) Exon Codon Base change
Amino acid
substitution
Nature of
mutation
15 0 4 1 0 4 C A GRCAT GlnRHis Missense
25 0 4 1 1 7 G GGRGTGG l y RVal Missense
3 1 5 126 TACRTTC TyrRPhe Missense
4 1 5 127 TCCRTTC SerRPhe Missense
51 0 5 1 2 7 TCCRCCC SerRPro Missense
61 0 5 1 2 7 T CCRTGC SerRCys Missense
71 0 5 1 2 8 C CTRCTTP r o RLeu Missense
8 10 5 138 GCC AAGRGTC CAA G Frameshift
95 0 5 1 4 1 TGCRCGC CysRArg Missense
10 50 5 152 CCGRCTG (CpG) ProRLeu Missense
11 10 5 163 TACRTAA TyrRStop Nonsense
12 10 5 175 CGCRCAC (CpG) ArgRHis Missense
13 10 5 177 CCCRCACP r o RHis Missense
14 10 5 179 CATRTAT HisRTyr Missense
15 1 5 181 CGCRAGC ArgRSer Missense
16 50 6 224 GAGRAAG GluRLys Missense
17–18 10,50 7 234 TACRCAC TyrRHis Missense
19 50 7 236 8 bases deletion Frameshift
20 1 7 242 TGCRTACC y s RTyr Missense
21 10 7 248 CGGRCCGA r g RPro Missense
22–23–24 10,10,50 7 248 CGGRCAG (CpG) ArgRGln Missense
25 1 7 251 ATCRACC IleRThr Missense
26 10 7 260 23 bases deletion Frameshift
27 50 7 260 24 bases deletion Frameshift
28 10 8 271 GAGRGAT GluRAsp Missense
29 10 8 277 TGTRTATC y s RTyr Missense
30 50 8 277 TGTRTTTC y s RPhe Missense
31 50 8 279 GGGRGAGG l y RGlu Missense
32 10 8 280 AGARGGA ArgRGly Missense
33–34 10,10 8 283 CGCRCAC (CpG) ArgRHis Missense
35 10 8 285 GAGRGAT GluRAsp Missense
36 10 8 288 AATRGAT AsnRAsp Missense
37 1 8 290 1 base deletion Frameshift
doi:10.1371/journal.pone.0030921.t002
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with various strains deficient in nucleotide excision repair, it was
demonstrated that DNA polymerases g and f were required in
combination for the translesion repair across BPDE adducts,
leading to G.T transversions [35]. Pol f alone was also able to
generate large deletions in this assay.
Depending on the experimental approach, discrepancies have
been observed between mutational patterns in TP53 induced by in
vitro and in vivo exposure to B[a]P or BPDE. Using the same yeast
assay as us, but after a direct BPDE exposure of a methylated
plasmid bearing the human TP53 sequence, Yoon et al. have found
a clear predominance of G.T transversions whereas Shen et al.
have found mainly G.A transitions [11,21]. The direct
sequencing of TP53 in human-p53 knock-in (Hupki) murine
embryonic fibroblasts after in vitro exposure to B[a]P have shown
mainly G.T transversions [36,37]. Similarly, G.T mutations
were also found predominantly in skin tumours after B[a]P
exposure [38]. The sequencing of TP53 from various tumours
induced after in vivo exposure of mice to B[a]P or coal tar led to the
same extent of G.T, G.A and G.C mutations [39]. On the
whole, it is clear from the vast majority of studies, that regardless of
the gene being studied and the biological system used, G.T
transversion is the hallmark of B[a]P or BPDE exposure. In this
regard, we were surprised to find these transversions accounting
for only 22% of mutations in our study, but rising from 17% at
1 mM to 27% at 50 mM. As suggested by Wei et al. [31], it may be
a matter of dose. Many in vitro studies have used BPDE in the mM
range [11,35] whereas we used B[a]P in the same range, which
obviously led to a lower exposure to BPDE in our protocol. Some
in vitro studies used B[a]P in the mM range, but in these studies the
time of exposure ranged from 4 to 9 days instead of the 2 hours in
our protocol [36,37]. This suggests that the G.T transversions
could be the hallmark of a strong exposure to B[a]P, a scenario
which appears plausible in the context of tobacco smoke exposure
in heavy smokers, whereas moderate exposure could lead to both
G.T, G.A, G.C and deletions, as found in many studies. This
hypothesis is supported by the prevalence of G.T transversions in
lung cancers with respect to tobacco exposure. According to IARC
database (Figure 5), this prevalence ranges from 25% in non
smokers to 32% in smokers and 55% in heavy smokers.
Conversely to the rate of G.T transversion, we found a high
rate of G.A transitions (38%), half of which being located in CpG
sequences. This could be partly explained by spontaneous
mutations as seen in control cells. But a technical bias may be
Figure 4. Codon distribution of single base substitutions in the TP53 gene. Mutational pattern as seen in AG1521 fibroblasts after B[a]P
(orange bars, n=32 mutations); AFB1 (pink bars, n=29 mutations); and acetaldehyde (blue bars, n=32 mutations) exposure. Codons typed in italic
are major hot-spots in human tumours according to IARC database.
doi:10.1371/journal.pone.0030921.g004
Figure 3. In vitro induced mutation patterns of TP53. (A) In vitro
Acetaldehyde-exposed human fibroblasts AG1521 (FASAY) (n=35
mutations, data from [15]), (B) In vitro AFB1-exposed human fibroblasts
AG1521 (FASAY) (n=37 mutations, data from [16]), (C) In vitro B[a]P-
exposed human fibroblasts AG1521 (FASAY) (n=37 mutations).
doi:10.1371/journal.pone.0030921.g003
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independently arising but identical mutation events and one of the
following situation: (i) multiple mRNA transcripts from the same
mutant cell that are subsequently independently captured into
plasmids or (ii) clonal expansion of a mutant cell before harvesting
of the pool of treated cells. In Table 2 only 3 mutations may be
potentially relevant of such bias, suggesting that artefactual
duplication of mutations might be infrequent. In addition,
duplicated mutations are mostly G.A transitions in CpG sites.
This may wrongly increase the rate of this particular mutation.
Comparison of TP53 mutational profiles obtained for the
genotoxins, B[a]P, acetaldehyde and AFB1
Results obtained from the application of FASAY to evaluate
mutagenic effects of in vitro exposure of normal human fibroblasts
to B[a]P, acetaldehyde and AFB1 were compared. Fisher’s exact
test revealed that in terms of the type of mutation, B[a]P and AFB1
patterns were not statistically different (p=0.6735), whereas the
differences between the patterns for acetaldehyde and either B[a]P
or AFB1 were statistically of borderline significance (p values of
0.0546 and 0.0705, respectively). These three compounds are
known to cause various types of DNA damages which could in
turn, be related to specific mutations. Acetaldehyde-induced
pattern is mainly characterized by a very high proportion of
G.A transitions (66%), mostly located within CpG sequences
which is a likely basis for the formation of interstrand crosslink
adducts in CpG sequences [15]. In contrast, the high rate of G.T
transversions observed among B[a]P- and AFB1-induced muta-
tions, has been recognized as a hallmark of their mutagenicity, in
vitro and in vivo [4,40]. This is mostly attributable to the presence of
bulky adducts.
B[a]P pattern reveals two unique features in comparison to
those of AFB1 and acetaldehyde: the occurrence of G.C
transitions and a higher rate of deletions (11% vs 5–6%). Whereas
AFB1 and acetaldehyde induced single-base deletions, B[a]P could
generate deletions up to 24 nucleotides. This feature may be the
result of a particular translesion synthesis pathway of B[a]P
adducts as discussed above.
Thus, a preliminary analysis using the FASAY enabled us to
record and distinguish different experimentally-generated muta-
tion patterns in TP53, which were then used to compare with
existing epidemiological data on maps of DNA adducts and
tumour mutations in TP53.
Occurrence of experimental TP53 mutants in human
tumours and functional impact of mutations
The pooled distribution of mutated codons obtained after
exposure to each of the three genotoxins discussed here allowed us
to identify 6 major hot-spots in human tumours, codons 248, 273,
175, 245, 282, 249 (Figure 4).
At the phenotypic level, among the 63 mutants resulting from a
nucleotide substitution, the two most frequently retrieved in
human tumours were also found in our experimental patterns, i.e.
Arg175His and Arg248Gln (Table 3). Moreover, four substitutions
(Arg175His, Arg248Gln, Arg273Cys and Gly245Ser) represent
together more than 10% of the mutants found in human tumours.
Only three mutants found in our study have never been described
in human tumours (Gly117Val, Gly262Leu, Asn288Ile). This
strongly suggests that FASAY recovers mutants bearing a
functional change allowing selection during the carcinogenesis
process.
We evaluated the functional consequence of mutations
occurring after in vitro exposure to three chemicals in the light of
the data from Dearth et al. that reviewed the impact of 76 TP53
mutants frequently observed in human tumours [12]. Fourteen out
of the 76 analysed mutants were retrieved in our three
experimental patterns (Table 3). As expected, these 14 mutants
were devoid of activity on RGC sequences which was used in our
FASAY protocol. This analysis indicates that most of the
experimental mutations harbour major functional impairment,
i.e. complete loss of transcriptional activity on 22 p53 DNA
Binding Sequences (DBS) and Dominant Negative Effect (DNE).
Conversely, some of the mutations that are frequent in human
tumours are unlikely to be retrieved by the FASAY because they
retain transcriptional activity [12]. This includes for instance
Arg175Leu or Glu285Lys that were not found in our assay.
However, the functional analysis of mutants by FASAY does not
enable us to discriminate between different types of cancers.
Indeed, if FASAY allow us to retrieve mutants occurring
frequently in human tumours, these mutants were neither
Figure 5. Mutation patterns of TP53: comparison vitro-vivo. From left to right: in vitro B[a]P-exposed human fibroblasts AG1521 (FASAY)
(n=37); human lung cancers, non smokers (n=288); human lung cancers, smokers (n=870); human lung cancers, heavy smokers (n=20). Lung
cancer data from IARC database R14. Rare mutations were omitted in these patterns.
doi:10.1371/journal.pone.0030921.g005
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to a particular genotoxin. For instance, Arg175His and
Arg248Gln found in B[a]P and AFB1 patterns are the most
frequently identified mutants in the human tumours, accounting
for 4.25% and 3.21% of all mutants respectively (Table 3), but
they account for only 1.2% of lung cancers or hepatocarcinoma
mutants according to IARC database. In the same way,
Arg273Cys depicted in the acetaldehyde pattern is more frequent
in the whole human tumour spectrum (2.44%) than in that for
oesophageal cancer (1.3%).
This analysis highlights the ability of chemicals to induce
frequent and highly impaired TP53 mutants which may be a key
event involved in the carcinogenesis. Compared with classical
mutagenesis assays using reporter genes, this functional in vitro
approach provides strong arguments for a biological plausibility of
carcinogenicity for a genotoxin. Nonetheless it recapitulates only
the initiating step of carcinogenesis and consequently is inaccurate
in predicting which particular mutation could be a driving force
during the subsequent steps of carcinogenesis in a given tissue.
This feature should be considered while comparing in vitro and in
vivo patterns of mutants.
Outlook
The FASAY performed after in vitro exposure of human normal
fibroblasts to various genotoxins allowed us to depict experimental
mutational patterns which share some, but not all, features of
tumour patterns. This makes the FASAY a relevant and powerful
tool to assess genotoxins implication in cancer aetiology, allowing a
direct comparison of experimental and human cancer patterns of
mutations.Indeed,demonstratingtheabilityofachemicaltoinduce
experimentally the same deleterious mutations in a key tumour
suppressor gene as found in relevant tumours provides a strong
weight of evidence of human carcinogenicity. Our earlier data on
acetaldehyde-induced mutations strongly suggest that alcohol acts
as a true genotoxin in the development of head and neck and
oesophageal tumours via production of acetaldehyde [15]. This
supports the findings from epidemiological studies which have
clearly shown that alcohol acts as a non-threshold carcinogen in
such cancers [41]. The experimental AFB1-induced pattern [16]
agreed with that found by other studies showing that G.T
transversion in codon 249 found in hepatocarcinoma is likely a
selection bias occurring during carcinogenesis [40,42]. Finally the
B[a]P pattern described in this study suggests that not only G.T
transversions but also deletions could be the hallmark of B[a]P-
exposure in lung tumours. Interestingly, a recent study using a
massive parallel sequencing technology has revealed the mutational
burden in a human small-cell lung cancer cell line, NCI-H209, after
exposure to carcinogens in tobacco smoke [43]. The most prevalent
mutationswereG.T (34%), G.A (21%)andA.G (19%), which is
in excellent agreement with mutations found in TP53 in lung
cancers. This highlights the fact that TP53 mutational pattern can
be considered as representative of the global mutational pattern
arising during lung carcinogenesis, reinforcing the relevance of
studying this gene as a key target for environmental carcinogens.
Finally, the ability of FASAY to study different biological
materials including either normal and cancerous differentiated
cells, or cancer stem cells, offers exciting perspectives to study
mutational patterns in order to improve our knowledge of human
chemical carcinogenesis.
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Table 3. Frequency in human tumours and functional impairment of some experimentally induced mutants.
Mutant Aetiology
(1) Rank
(2)
Nr of occurrence
and frequency (%)
in human tumours
(3)
Loss of
transcriptional
activity
(4)
Dominant
negative
effect
(5)
Arg175His AFB1 17, B[a]P 12 1 1130 (4.25) ++ ++
Arg248Gln Ac 18–21, B[a]P 22–24 2 855 (3.21) ++ ++
Arg273Cys Ac 27–28 5 650 (2.44) ++ 2
Gly245Ser Ac 14–16, AFB1 31–35 8 423 (1.60) ++ ++
His179Tyr B[a]P 14 19 104 (0.39) ++ ++
Pro151Ser AFB1 12 27 96 (0.36) ++ +
Pro278Leu Ac 29–30 37 79 (0.30) ++ +
Gly244Asp AFB1 27–28 56 60 (0.23) ++ ++
Gly279Glu B[a]P 31 69 48 (0.18) ++ ++
Cys277Tyr B[a]P 29 101 28 (0.11) ++ +
Arg267Trp Ac 25–26 119 27 (0.10) ++ +
His179Asn AFB1 18–20 128 23 (0.09) ++ ++
Arg283His Ac 31–33, AFB1 39, B[a]P 33–34 277 17 (0.06) ++ /2
Ser127Pro B[a]P 5 417 6 (0.02) ++ ++
The table shows the 14 mutants induced by acetaldehyde (Ac), B[a]Po rA F B 1 for which exhaustive functional data were available from Dearth et al. [12].
(1)The number refers to the identity of the mutant in the corresponding paper: Ac, table 3 from [15]; AFB1, table 3 from [16]; B[a]P, table 2 from the present work.
(2)According to Dearth et al. [12].
(3)According to IARC database R14.
(4)++: loss of transcriptional activity on the 22 p53 DBS tested; +: loss of transcriptional activity on 13 DBS only [12].
(5)++: DNE on the 11 DBS tested; +: DNE on more than 5 DBS; +/2: DNE on 3 DBS only; 2: no DNE [12].
doi:10.1371/journal.pone.0030921.t003
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